Ibezapolstat

Ibezapolstat is Acurx's lead oral antibiotic candidate for Clostridioides difficile infection (CDI), including recurrent CDI strategies. It is being advanced into international Phase 3 registration trials after Phase 2 results. The drug belongs to a new DNA polymerase IIIC inhibitor class and is still investigational.

Drug Class

DNA polymerase IIIC inhibitor antibacterial (Gram-positive selective spectrum)

Approval Status

Investigational candidate in Phase 3 planning/registration development; not yet approved.

Mechanism of Action

Blocks the active site of bacterial DNA polymerase IIIC, inhibiting DNA replication and causing Gram-positive bacterial cell death.